Azam M, Hudgi A, Uy PP, Makhija J, Yap JEL. Safety of endoscopy in patients undergoing treatments with antiangiogenic agents: A 5-year retrospective review. World J Gastrointest Endosc 2022; 14(7): 416-423 [PMID: 36051996 DOI: 10.4253/wjge.v14.i7.416]
Corresponding Author of This Article
John Erikson L Yap, MD, Assistant Professor, Division of Gastroenterology, Medical College of Georgia/Augusta University, 1120 15th Street, Augusta, GA 30912, United States. jyap@augusta.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 3 Total endoscopic procedures performed and complications
Endoscopic procedures (n = 85)
1 Esophagogastroduodenoscopy
56
(A) With biopsy
17
(B) With variceal banding
10
(C) With stent
2
(D) With pneumatic dilation
1
(E) With percutaneous gastrostomy tube placement
8
(F) Enteroscopy
1
2 Flexible sigmoidoscopy
6
(A) With biopsy
2
3 Colonoscopy
23
(A) With biopsy
7
(B) With snare
3
(C) With control of bleeding
2
(D) With stent placement
1
Complications
1 Perforation
0
2 Bleeding
2 (2.35%)
Mortality
2 (2.35%)
Table 4 List of antiangiogenic agents
Anti-angiogenic agents (n = 60)
Vascular-endothelial growth factor inhibitors
1 Bevacizumab
30
2 Ramucirumab
3
3 Lenvatinib
4
4 Sorafenib
2
Epidermal-growth factor receptor inhibitors
1 Cetuximab
3
2 Osimertinib
1
Tyrosine-kinase inhibitors
1 Lapatinib
1
2 Pazopanib
2
3 Imatinib
7
4 Dasatinib
1
5 Sunitinib
2
Mammalian target of rapamycin inhibitor
1 Everolimus
2
2 Temsirolimus
2
Citation: Azam M, Hudgi A, Uy PP, Makhija J, Yap JEL. Safety of endoscopy in patients undergoing treatments with antiangiogenic agents: A 5-year retrospective review. World J Gastrointest Endosc 2022; 14(7): 416-423